1
|
Zhou Y, Lauschke VM. Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. Hum Genet 2022; 141:1113-1136. [PMID: 34652573 PMCID: PMC9177500 DOI: 10.1007/s00439-021-02385-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Accepted: 10/05/2021] [Indexed: 11/25/2022]
Abstract
Both safety and efficacy of medical treatment can vary depending on the ethnogeographic background of the patient. One of the reasons underlying this variability is differences in pharmacogenetic polymorphisms in genes involved in drug disposition, as well as in drug targets. Knowledge and appreciation of these differences is thus essential to optimize population-stratified care. Here, we provide an extensive updated analysis of population pharmacogenomics in ten pharmacokinetic genes (CYP2D6, CYP2C19, DPYD, TPMT, NUDT15 and SLC22A1), drug targets (CFTR) and genes involved in drug hypersensitivity (HLA-A, HLA-B) or drug-induced acute hemolytic anemia (G6PD). Combined, polymorphisms in the analyzed genes affect the pharmacology, efficacy or safety of 141 different drugs and therapeutic regimens. The data reveal pronounced differences in the genetic landscape, complexity and variant frequencies between ethnogeographic groups. Reduced function alleles of CYP2D6, SLC22A1 and CFTR were most prevalent in individuals of European descent, whereas DPYD and TPMT deficiencies were most common in Sub-Saharan Africa. Oceanian populations showed the highest frequencies of CYP2C19 loss-of-function alleles while their inferred CYP2D6 activity was among the highest worldwide. Frequencies of HLA-B*15:02 and HLA-B*58:01 were highest across Asia, which has important implications for the risk of severe cutaneous adverse reactions upon treatment with carbamazepine and allopurinol. G6PD deficiencies were most frequent in Africa, the Middle East and Southeast Asia with pronounced differences in variant composition. These variability data provide an important resource to inform cost-effectiveness modeling and guide population-specific genotyping strategies with the goal of optimizing the implementation of precision public health.
Collapse
Affiliation(s)
- Yitian Zhou
- Department of Physiology and Pharmacology, Karolinska Institutet, 171 77, Stockholm, Sweden
| | - Volker M Lauschke
- Department of Physiology and Pharmacology, Karolinska Institutet, 171 77, Stockholm, Sweden.
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
| |
Collapse
|
2
|
Mirzaev K, Abdullaev S, Akmalova K, Sozaeva J, Grishina E, Shuev G, Bolieva L, Sozaeva M, Zhuchkova S, Gimaldinova N, Sidukova E, Serebrova S, Asoskova A, Shein A, Poptsova M, Suleymanov S, Burashnikova I, Shikaleva A, Kachanova A, Fedorinov D, Sychev D. Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers. Pharmacogenomics 2020; 21:677-694. [DOI: 10.2217/pgs-2020-0005] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background: The aim of this study was to determine the prevalence of CYP2C9, VKORC1, CYP2C19, ABCB1, CYP2D6 and SLCO1B1 genes polymorphisms among residents of the Volga region (Chuvash and Mari) and northern Caucasus (Kabardins and Ossetians). Materials & methods: The study involved 845 apparently healthy volunteers of both sexes of the four different ethnic groups living in the Russian Federation: 238 from the Chuvash ethnic group, 206 Mari, 157 Kabardins and 244 Ossetians. Results: Significant differences were identified in allele frequency of CYP2C9, VKORC1, CYP2C19, ABCB1, CYP2D6 and SLCO1B1 genes polymorphisms between the Chuvash and Kabardins, Chuvash and Ossetians, Mari and Kabardians, Mari and Ossetians.
Collapse
Affiliation(s)
- Karin Mirzaev
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of The Ministry of Healthcare of The Russian Federation, Barrikadnaya Str., 2/1, Bldg. 1, Moscow, 125993, Russian Federation
| | - Sherzod Abdullaev
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of The Ministry of Healthcare of The Russian Federation, Barrikadnaya Str., 2/1, Bldg. 1, Moscow, 125993, Russian Federation
| | - Kristina Akmalova
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of The Ministry of Healthcare of The Russian Federation, Barrikadnaya Str., 2/1, Bldg. 1, Moscow, 125993, Russian Federation
| | - Jeannette Sozaeva
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of The Ministry of Healthcare of The Russian Federation, Barrikadnaya Str., 2/1, Bldg. 1, Moscow, 125993, Russian Federation
| | - Elena Grishina
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of The Ministry of Healthcare of The Russian Federation, Barrikadnaya Str., 2/1, Bldg. 1, Moscow, 125993, Russian Federation
| | - Gregory Shuev
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of The Ministry of Healthcare of The Russian Federation, Barrikadnaya Str., 2/1, Bldg. 1, Moscow, 125993, Russian Federation
| | - Laura Bolieva
- Federal State Budgetary Educational Institution of Higher Education “North Ossetia State Medical Academy” of The Ministry of Healthcare of the Russian Federation, Pushkinskaya Str., 40, Vladikavkaz, Republic of North Ossetia–Alania, 362019, Russian Federation
| | - Mariam Sozaeva
- State Budgetary Healthcare Institution “Republican Clinical Hospital” of The Ministry of Healthcare of The Russian Federation, Nogmova Str., 91, Nalchik, Kabardino–Balkarian Republic, 360003, Russian Federation
| | - Svetlana Zhuchkova
- Autonomous Institution “Republican Clinical Oncology Center” of the Ministry of Health of The Chuvash Republic, Gladkov Str., 31, Cheboksary, Chuvash Republic, 428020, Russian Federation
| | - Natalya Gimaldinova
- Federal State Budgetary Educational Institution of Higher Education “I. N. Ulianov Chuvash State University”, Moskovskiy Pr., 15, Cheboksary, Chuvash Republic, 428015, Russian Federation
| | - Elena Sidukova
- State Budgetary Institution of The Republic of Mari El ‘Kozmodemyansk interdistrict hospital”, 3rd microdistrict, 25, Kozmodemyansk, Republic of Mari El, 425350, Russian Federation
| | - Svetlana Serebrova
- Department of Clinical Pharmacology & Propaedeutic of Internal Diseases of The Faculty of General Medicine of Sechenov First Moscow State Medical University of The Ministry of Health of The Russian Federation, Trubetskaya Str., 8, bld., Moscow, 2119991, Russian Federation
| | - Anastasia Asoskova
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of The Ministry of Healthcare of The Russian Federation, Barrikadnaya Str., 2/1, Bldg. 1, Moscow, 125993, Russian Federation
| | - Alexander Shein
- Laboratory of Bioinformatics, Big Data & Information Retrieval School, Faculty of Computer Science, National Research University Higher School of Economics, 3 Kochnovsky Proezd, Moscow, 109028, Russian Federation
| | - Maria Poptsova
- Laboratory of Bioinformatics, Big Data & Information Retrieval School, Faculty of Computer Science, National Research University Higher School of Economics, 3 Kochnovsky Proezd, Moscow, 109028, Russian Federation
| | - Salavat Suleymanov
- Russian–Japanese Medical Center “SAIKO”, Komsomolskaya St., 104, Khabarovsk, Khabarovsk Territory, 680000, Russian Federation
| | - Irina Burashnikova
- Kazan State Medical Academy, Kazan State Medical University, Mushtari st., 11, Kazan, Republic of Tatarstan, 420012, Russian Federation
| | - Anastasia Shikaleva
- Kazan State Medical Academy, Kazan State Medical University, Mushtari st., 11, Kazan, Republic of Tatarstan, 420012, Russian Federation
| | - Anastasia Kachanova
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of The Ministry of Healthcare of The Russian Federation, Barrikadnaya Str., 2/1, Bldg. 1, Moscow, 125993, Russian Federation
| | - Denis Fedorinov
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of The Ministry of Healthcare of The Russian Federation, Barrikadnaya Str., 2/1, Bldg. 1, Moscow, 125993, Russian Federation
| | - Dmitry Sychev
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of The Ministry of Healthcare of The Russian Federation, Barrikadnaya Str., 2/1, Bldg. 1, Moscow, 125993, Russian Federation
| |
Collapse
|
3
|
Naranjo MEG, de Andrés F, Delgado A, Cobaleda J, Peñas-Lledó EM, LLerena A. High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies. THE PHARMACOGENOMICS JOURNAL 2016; 16:485-90. [PMID: 27272044 DOI: 10.1038/tpj.2016.47] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Revised: 03/14/2016] [Accepted: 05/02/2016] [Indexed: 02/06/2023]
Abstract
A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has been claimed to exist among Spaniards and Southern Europeans. However, methodological aspects such as the inclusion of individuals carrying non-active multiplied alleles as gUMs may have led to an overestimation. Thus, this study aimed to analyze the gUM frequency (considering only those carrying more than two active genes) in 805 Spanish healthy volunteers studied for CYP2D6*2, *3, *4, *5, *6, *10, *17, *35, *41, and multiplications. Second, all worldwide studies reporting gUM frequencies were reviewed in order to evaluate potential misclassifications. The gUM frequency in this Spanish population was 5.34%, but increased to 8.3% if all individuals with CYP2D6 multiplications were classified as gUMs without considering the activity of the multiplied alleles. Moreover, among all reviewed worldwide studies only 55.6% precisely determined whether the multiplied alleles were active. Present results suggest that the evaluation of CYP2D6 ultrarapid metabolism should be standarized, and that the frequency of gUMs should be reconsidered in Spaniards and globally.
Collapse
Affiliation(s)
- M E G Naranjo
- CICAB Clinical Research Center, Extremadura University and Medical School, Badajoz, Spain
| | - F de Andrés
- CICAB Clinical Research Center, Extremadura University and Medical School, Badajoz, Spain
| | - A Delgado
- CICAB Clinical Research Center, Extremadura University and Medical School, Badajoz, Spain
| | - J Cobaleda
- CICAB Clinical Research Center, Extremadura University and Medical School, Badajoz, Spain.,Primary Health Care Center 'Ciudad Jardín', Badajoz, Spain
| | - E M Peñas-Lledó
- CICAB Clinical Research Center, Extremadura University and Medical School, Badajoz, Spain
| | - A LLerena
- CICAB Clinical Research Center, Extremadura University and Medical School, Badajoz, Spain.,CIBERSAM, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
4
|
ADLER G, PAWIŃSKA-MATECKA A, GARSTKA A, SALKIC NN, VALJEVAC A, KARAKIEWICZ B. First report on the distribution of 3435C>T ABCB1/MDR1polymorphism in healthy Bosniak population. Turk J Med Sci 2016; 46:942-4. [DOI: 10.3906/sag-1410-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2014] [Accepted: 07/27/2015] [Indexed: 11/03/2022] Open
|
5
|
Gbandi E, Goulas A, Sevastianos V, Hadziyannis S, Panderi A, Koskinas J, Papatheodoridis G, Vasiliadis T, Agapakis D, Protopapas A, Ioannidou P, Zacharakis G, Sinakos E, Koutsounas S, Germanidis G. Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population. Pharmacol Rep 2015; 68:476-82. [PMID: 26922556 DOI: 10.1016/j.pharep.2015.10.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Revised: 10/23/2015] [Accepted: 10/23/2015] [Indexed: 01/18/2023]
Abstract
BACKGROUND Hepatitis C virus infectivity and replication efficiency appears to be dependent on the lipid content and organization of the plasma membrane of the host cell, as well as of the intracellular membranous web. As there is increasing awareness of a role played by the efflux pump ABCB1 (p-glycoprotein, P-gp) in lipid homeostasis, its function could be a determinant of chronic HCV infection. The aim of the present study was to examine and compare the distribution of common ABCB1 genotypes in patients with chronic HCV infection (n=168), hyperlipidemic patients (n=168) and a control group (n=173), all from Greece. METHODS Participants were genotyped for the ABCB12677G>T/A and 3435C>T polymorphisms with previously reported PCR-RFLP methods. Genotype and allele frequency distributions were compared between the three groups with the χ(2) test of independence. RESULTS The ABCB1 2677GG (ancestral) genotypes were significantly over-represented in patients with chronic hepatitis C compared to controls (39.3% vs. 26.6%, p=0.015 according to the dominant model). A similar result was obtained when hyperlipidemic patients were compared to controls (45.2% vs. 26.6%, p<0.001 according to the dominant model). Comparison of ABCB1 3435C>T genotype and allele distributions provided similar but not as significant differences. Genotype and allele distributions for both ABCB12677G>T/A and 3435C>T were very similar between HCV patients and hyperlipidemic patients. CONCLUSION Our findings imply an influence of ABCB1 polymorphisms on HCV infectivity, possibly through an effect on lipid homeostasis.
Collapse
Affiliation(s)
- Emma Gbandi
- 1st Department of Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Antonis Goulas
- 1st Department of Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
| | | | | | - Athanasia Panderi
- 1st Department of Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - John Koskinas
- 2nd Academic Department of Internal Medicine, Hippokration Hospital of Athens, Athens, Greece
| | - George Papatheodoridis
- Department of Gastroenterology, Athens University Medical School, Laikon General Hospital of Athens, Athens, Greece
| | - Themistoklis Vasiliadis
- 3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Dimitrios Agapakis
- 1st Propedeutic Department of Internal Medicine, AHEPA Hospital, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Andreas Protopapas
- 1st Propedeutic Department of Internal Medicine, AHEPA Hospital, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Panagiota Ioannidou
- Department of Gastroenterology, Athens University Medical School, Laikon General Hospital of Athens, Athens, Greece
| | - George Zacharakis
- 2nd Department of Gastroenterology, Evangelismos General Hospital of Athens, Athens, Greece
| | - Emmanuil Sinakos
- 4th Department of Internal Medicine, Aristotle University of Thessaloniki Medical School, Hippokration General Hospital, Thessaloniki, Greece
| | | | - Georgios Germanidis
- 1st Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece
| |
Collapse
|
6
|
Gaio V, Picanço I, Nunes B, Fernandes A, Mendonça F, Horta Correia F, Beleza Á, Gil AP, Bourbon M, Vicente A, Matias Dias C, Barreto da Silva M. Pharmacogenetic Profile of a South Portuguese Population: Results from the Pilot Study of the European Health Examination Survey in Portugal. Public Health Genomics 2015; 18:139-50. [DOI: 10.1159/000373920] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Accepted: 01/08/2015] [Indexed: 01/19/2023] Open
|
7
|
Mustafina OE, Tuktarova IA, Karimov DD, Somova RS, Nasibullin TR. CYP2D6, CYP3A5, and CYP3A4 gene polymorphisms in Russian, Tatar, and Bashkir populations. RUSS J GENET+ 2015. [DOI: 10.1134/s1022795415010081] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
8
|
LLerena A, Naranjo MEG, Rodrigues-Soares F, Penas-LLedó EM, Fariñas H, Tarazona-Santos E. Interethnic variability ofCYP2D6alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol 2014; 10:1569-83. [DOI: 10.1517/17425255.2014.964204] [Citation(s) in RCA: 112] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
9
|
Santos M, Carvalho S, Lima L, Nogueira A, Assis J, Mota-Pereira J, Pimentel P, Maia D, Correia D, Gomes S, Cruz A, Medeiros R. Common genetic polymorphisms in the ABCB1 gene are associated with risk of major depressive disorder in male Portuguese individuals. Genet Test Mol Biomarkers 2013; 18:12-9. [PMID: 24200053 DOI: 10.1089/gtmb.2013.0197] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Major depressive disorder (MDD) is a highly prevalent disorder, which has been associated with an abnormal response of the hypothalamus-pituitary-adrenal (HPA) axis. Reports have argued that an abnormal HPA axis response can be due to an altered P-Glycoprotein (P-GP) function. This argument suggests that genetic polymorphisms in ABCB1 may have an effect on the HPA axis activity; however, it is still not clear if this influences the risk of MDD. Our study aims to evaluate the effect of ABCB1 C1236T, G2677TA and C3435T genetic polymorphisms on MDD risk in a subset of Portuguese patients. DNA samples from 80 MDD patients and 160 control subjects were genotyped using TaqMan SNP Genotyping assays. A significant protection for MDD males carrying the T allele was observed (C1236T: odds ratio (OR)=0.360, 95% confidence interval [CI]: [0.140-0.950], p=0.022; C3435T: OR=0.306, 95% CI: [0.096-0.980], p=0.042; and G2677TA: OR=0.300, 95% CI: [0.100-0.870], p=0.013). Male Portuguese individuals carrying the 1236T/2677T/3435T haplotype had nearly 70% less risk of developing MDD (OR=0.313, 95% CI: [0.118-0.832], p=0.016, FDR p=0.032). No significant differences were observed regarding the overall subjects. Our results suggest that genetic variability of the ABCB1 is associated with MDD development in male Portuguese patients. To the best of our knowledge, this is the first report in Caucasian samples to analyze the effect of these ABCB1 genetic polymorphisms on MDD risk.
Collapse
Affiliation(s)
- Marlene Santos
- 1 Molecular Oncology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology , Porto, Porto, Portugal
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Albuquerque J, Ribeiro C, Naranjo MEG, Llerena A, Grazina M. Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications. Per Med 2013; 10:709-718. [DOI: 10.2217/pme.13.56] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Aim:CYP2D6 codes for a protein that is vastly involved in the metabolism of various substances. This gene is highly polymorphic, which influences the enzymatic activity and contributes to the huge variability in the enzyme hydroxylation capacity. Different metabolic profiles determine the processing of xenobiotics and endobiotics, thereby influencing disease risk, therapeutic efficacy and side effects, or toxicity of xenobiotics. The aim of this work was to characterize CYP2D6 polymorphisms and predict metabolic profiles in the Portuguese population. Subjects & methods: The study comprised 300 Portuguese unrelated healthy adult volunteers. Genetic analysis included allelic discrimination and copy number determination with TaqMan® probes by real-time PCR and allele duplications of CYP2D6*1, CYP2D6*2, CYP2D6*4 and CYP2D6*10 were confirmed by long PCR and PCR-RFLP. Results: The percentages of poor and ultrarapid metabolizers found in this Portuguese population were 6.3 and 4.7%, respectively. Discussion & conclusion: Compared with other studies, such as in Spaniards, the allelic frequencies observed were similar, with some exceptions, such as for CYP2D6*10, which is higher in the Portuguese population, and for CYP2D6*6 and duplication of *1 and *2, appearing in lower frequencies in the present study. These results allow the determination of the frequency of the most relevant CYP2D6 polymorphisms and the prediction of the enzyme metabolic activity, being of much importance for the CYP2D6 pharmacogenetics approach in the Portuguese population. The data presented here are significant for the study of genetic variability influencing CYP2D6 activity, to improve the effectiveness and safety of xenobiotics exposure, also can be used as a tool in clinical practice for the development of individualized pharmacotherapy.
Collapse
Affiliation(s)
| | - Carolina Ribeiro
- CNC – Center for Neuroscience & Cell Biology, University of Coimbra, Portugal
| | - Maria Eugenia G Naranjo
- CICAB Clinical Research Centre, Extremadura University Hospital & Medical School, Badajoz, Spain
| | - Adrián Llerena
- CICAB Clinical Research Centre, Extremadura University Hospital & Medical School, Badajoz, Spain
| | - Manuela Grazina
- CNC – Center for Neuroscience & Cell Biology, University of Coimbra, Portugal
- Faculty of Medicine, University of Coimbra, Portugal
| |
Collapse
|
11
|
Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 2011; 27:9-54. [PMID: 22123129 DOI: 10.2133/dmpk.dmpk-11-rv-111] [Citation(s) in RCA: 183] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Drug lag, recently discussed extensively in Japan, can be divided into two phases: clinical development time and application review time. The former factor is still an important problem that might be improved by promoting multi-regional clinical trials and considering the results from other similar populations with Japanese, such as Koreans and Chinese. In this review, we compare the allelic or genotype frequencies of 30 relatively common functional alleles mainly between Eastern Asians and Europeans as well as among 3 major populations in Eastern Asian countries, Japan, Korea, and China, in 12 pharmacokinetics (PK)/pharmacodynamics (PD)-related genes; CYP2C9 (*2 and *3), CYP2C19 (*2, *3 and *17), 13 CYP2D6 haplotypes including *4, *5 and *10, CYP3A5 (*3), UGT1A1 (*28 and *6), NAT2 (*5, *6 and *7), GSTM1 and GSTT1 null genotypes, SLCO1B1 521T>C, ABCG2 421C>A, and HLA-A*31:01 and HLA-B*58:01. In this review, differences in allele frequencies (AFs) or genotype frequencies (GFs) less than 0.1 (in the cases of highest AF (GF) ≥0.1) or less than 0.05 (in the cases of lowest AF (GF) <0.1) were regarded as similar. Between Eastern Asians and Europeans, AFs (or GFs) are regarded as being different for many alleles such as CYP2C9 (*2), CYP2C19 (*2, *3 and *17), CYP2D6 (*4 and *10), CYP3A5 (*3), UGT1A1 (*28 and *6), NAT2 (*5*7), GSTT1 null and ABCG2 421C>A. Among the 3 Eastern Asian populations, however, only AFs of CYP2C19*3, CYP2D6*10, HLA-A*31:01 and HLA-B*58:01 are regarded as dissimilar. For CYP2C19*3, the total functional impact on CYP2C19 could be small if the frequencies of the two null alleles CYP2C19*2 and *3 are combined. Regarding CYP2D6*10, frequency difference over 0.1 is observed only between Japanese and Chinese (0.147). Although environmental factors should be considered for PK/PD differences, we could propose that among Japan, Korea, and China, genetic differences are very small for the analyzed common PK-related gene polymorphisms. On the other hand, AFs of the two HLA alleles important for cutaneous adverse drug reactions are diverse even among Eastern Asians and thus should be taken into account.
Collapse
Affiliation(s)
- Kouichi Kurose
- Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan
| | | | | |
Collapse
|
12
|
Rideg O, Háber Á, Botz L, Szücs F, Várnai R, Miseta A, Kovács GL. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population. Cell Biochem Funct 2011; 29:562-8. [DOI: 10.1002/cbf.1788] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2011] [Revised: 04/23/2011] [Accepted: 06/23/2011] [Indexed: 12/30/2022]
Affiliation(s)
- Orsolya Rideg
- Institute of Laboratory Medicine; University of Pécs; Pécs; Hungary
| | - Ágota Háber
- Department of Pharmaceutics and Central Clinical Pharmacy; University of Pécs; Pécs; Hungary
| | - Lajos Botz
- Department of Pharmaceutics and Central Clinical Pharmacy; University of Pécs; Pécs; Hungary
| | - Ferenc Szücs
- Department of Pharmaceutics and Central Clinical Pharmacy; University of Pécs; Pécs; Hungary
| | - Réka Várnai
- Institute of Family Medicine; University of Pécs; Pécs; Hungary
| | - Attila Miseta
- Institute of Laboratory Medicine; University of Pécs; Pécs; Hungary
| | | |
Collapse
|
13
|
Rodríguez Arcas M, García-Jiménez E, Martínez-Martínez F, Conesa-Zamora P. Papel del citocromo P450 en la farmacocinética y en la farmacogenética de los fármacos antihipertensivos. FARMACIA HOSPITALARIA 2011; 35:84-92. [DOI: 10.1016/j.farma.2010.05.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2010] [Revised: 05/20/2010] [Accepted: 05/28/2010] [Indexed: 01/10/2023] Open
|
14
|
Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS, Abreu RL, Oliveira GG, Vicente AM. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. THE PHARMACOGENOMICS JOURNAL 2009; 10:418-30. [PMID: 19997080 DOI: 10.1038/tpj.2009.63] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Little has been reported on the factors, genetic or other, that underlie the variability in individual response, particularly for autism. In this study we simultaneously explored the effects of multiple candidate genes on clinical improvement and occurrence of adverse drug reactions, in 45 autistic patients who received monotherapy with risperidone up to 1 year. Candidate genes involved in the pharmacokinetics (CYP2D6 and ABCB1) and pharmacodynamics (HTR2A, HTR2C, DRD2, DRD3, HTR6) of the drug, and the brain-derived neurotrophic factor (BDNF) gene, were analysed. Using the generalized estimating equation method these genes were tested for association with drug efficacy, assessed with the Autism Treatment Evaluation Checklist, and with safety and tolerability measures, such as prolactin levels, body mass index (BMI), waist circumference and neurological adverse effects, including extrapyramidal movements. Our results confirm that risperidone therapy was very effective in reducing some autism symptoms and caused few serious adverse effects. After adjusting for confounding factors, the HTR2A c.-1438G>A, DRD3 Ser9Gly, HTR2C c.995G>A and ABCB1 1236C>T polymorphisms were predictors for clinical improvement with risperidone therapy. The HTR2A c.-1438G>A, HTR2C c.68G>C (p.C33S), HTR6 c.7154-2542C>T and BDNF c.196G>A (p.V66M) polymorphisms influenced prolactin elevation. HTR2C c.68G>C and CYP2D6 polymorphisms were associated with risperidone-induced increase in BMI or waist circumference. We thus identified for the first time several genes implicated in risperidone efficacy and safety in autism patients. Although association results require replication, given the small sample size, the study makes a preliminary contribution to the personalized therapy of risperidone in autism.
Collapse
Affiliation(s)
- C T Correia
- Instituto Gulbenkian de Ciência, Oeiras, Portugal
| | | | | | | | | | | | | | | | | |
Collapse
|